DILI : An AI-Based Classifier to Search for Drug-Induced Liver Injury Literature

Sanjay Rathee1, Meabh MacMahon1,2, Anika Liu1,3

  • 1Milner Therapeutics Institute, University of Cambridge, Cambridge, United Kingdom.

Frontiers in Genetics
|July 18, 2022
PubMed

Insights

An AI model accurately identifies drug-induced liver injury (DILI) from research literature, improving drug discovery. This tool aids researchers by automating DILI article retrieval, reducing errors and saving time.

Area of Science:

  • Biomedical Informatics
  • Pharmacology
  • Artificial Intelligence

Background:

  • Drug-induced liver injury (DILI) is a significant cause of acute liver failure and drug development attrition.
  • Current methods for identifying DILI from literature are manual, inefficient, and prone to human error.
  • Automated retrieval of DILI information is crucial for the drug discovery community.

Purpose of the Study:

  • To develop an automated artificial intelligence (AI) model for efficient retrieval of DILI-related research articles.
  • To enhance the accuracy and speed of identifying potential drug-induced liver injury cases from scientific literature.

Main Methods:

  • Utilized natural language processing (NLP) for text filtering and keyword extraction (singletons, pairs, triplets).
  • Employed an apriori pattern mining algorithm to identify relevant patterns for machine learning (ML) classification.
  • Integrated pattern importance, frequency, and FDA-approved drug lists to train and validate the DILI classifier.

Main Results:

  • Developed a DILI classifier (DILI) achieving 94.91% cross-validation accuracy.
  • Attained 94.14% accuracy on external validation datasets.
  • Created an accessible R Shiny app for user-friendly DILI classification of single or multiple entries.

Conclusions:

  • The AI-powered DILI classifier significantly improves the efficiency and accuracy of identifying drug-induced liver injury from scientific literature.
  • The developed R Shiny application provides a valuable, accessible tool for researchers, including those without coding expertise.
  • This automated approach supports the drug discovery process by streamlining the identification of potential DILI risks.